Graham Lewis

1 month ago | mondaq.com | Graham Lewis |David Power |Dan G. Hilton

Welcome to the latest edition of the J A Kemp annual review ofEPO Board of Appeal decisions relating to antibody inventions. Thisyear we are reviewing decisions published between 31 January 2024and 31 December 2024. Overall, the majority of the decisionspublished in this interval followed current EPO examiner practicefor antibody inventions, as codified in the EPO's Guidelinesfor Examination (G-II, 6 – also discussed in our advanced guide).

Nov 28, 2024 | mondaq.com | Ravi Srinivasan |Graham Lewis

The European Commission has today imposed a €462.6 million antitrust fine on Teva for abusing its dominant position in the market for Copaxone, a blockbuster drug for treating multiple sclerosis. Teva's abusive conduct was said to consist of prolonging legal uncertainty over the enforceability of its patents for Copaxone, and disparaging a rival's generic version.

Jun 24, 2024 | footyalmanac.com.au | Graham Lewis

I thought I knew Baz!After all, we studied together for our Physical Education degrees in the 1980s at SACAE in Adelaide, now the University of South Australia. The course was renowned nationally, and the standards were high. Barry and I spent countless hours in the library as part of an informal study group. Both of us were district cricketers, playing for the now-defunct Student Teachers Cricket Club in the SACA District Competition.

May 20, 2024 | mondaq.com | Graham Lewis |James Egleton |James Smythies

The UK courts have been reasonably active in the SPC field recently, with two cases in particular catching our attention. In the first case, the High Court of England and Wales heard an appeal from a decision of the UKIPO to refuse Merck Serono's SPC application for cladribine, which turned on the applicability in the UK of the CJEU judgment in Santen (C-673/18). As is explained in more detail below, the Court held as expected that Santen applies in the UK ex tunc.

May 16, 2024 | mondaq.com | Vicki Allen |Marc Wilkinson |Graham Lewis

Broadcast date: 2 May 2024 — Speakers: Vicki Allen, Marc Wilkinson, Graham Lewis The European Patent Office (EPO) applies the same basic patentability criteria to antibodies as to other inventions. However, the high volume of applications in this area means that examiners have developed standardised approaches to assessing "antibody-specific" issues and these have been formalised in a dedicated section of the EPO's Guidelines for Examination.